FILING ANALYSIS · MONDAY, OCTOBER 26
Gsk GSK — RNS: Ris Rez Positive Ph 3 Osteosarcoma Data In China
positive
GSK's Ris-Rez showed a 67% reduction in the risk of disease progression or death in a Phase III trial for relapsed osteosarcoma in China, supporting a regulatory submission and informing the global development program
How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.
Get filings like this every market day
The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.
Subscribe free →